News
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...
Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...
2d
News Medical on MSNWeight loss benefits of Tirzepatide persist after stopping treatment in Chinese adults
In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...
Arrowhead Pharmaceuticals has dosed the first participant in the Phase I/IIa AROALK7-1001 trial of ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. The ...
HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...
Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.
A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results